In a significant scientific breakthrough, India has carried out its first human gene therapy trial for haemophilia. The breakthrough is the result of a joint effort between the Biotechnology Research and Innovation Council's Institute for Stem Cell Science and Regenerative Medicine (BRIC-inStem) in Bengaluru and Christian Medical College (CMC) Vellore.

Key HighlightsFirst Gene Therapy Trial for Haemophilia
The trial is India's first gene therapy effort aimed at haemophilia, a genetic disorder with low prevalence, affecting the clotting ability of the blood and causing excessive bleeding.

Carried out by BRIC-inStem and CMC Vellore
It was led by BRIC-inStem in Bengaluru, along with CMC Vellore, illustrating increased clinical-research integration in India.

Union Minister Reviews Facilities
Union Science & Technology Minister Dr. Jitendra Singh inspected the infrastructure at BRIC-inStem, including the Biosafety Level III facility and the recently established CREATE (Centre for Research Application and Training in Embryology).

Emphasis on Preventive & Regenerative Healthcare
The minister welcomed BRIC-inStem's efforts in preventive and regenerative medicine, terming the success a breakthrough in science-based nation-building.

Growth of Biotech Sector
India's biotech industry has grown 16 times in the past decade to $165.7 billion in 2024 and is expected to reach $300 billion in 2030.

Quotes of Officials or Leaders
Dr. Jitendra Singh, Union Minister of Science and Technology:
"This is not merely science, it's nation-building. Biotechnology has become a cornerstone of our national agenda, and is a major driver in building India's future in terms of health and economy."India's first successful trial of gene therapy for haemophilia marks a significant breakthrough in healthcare innovation. With increasing investment in biotechnology and an emphasis on clinical cooperation, India is emerging as a world leader in cutting-edge medical research and regenerative medicine.